←
Exon 20 Group, a multistakeholder organization2,070 posts
Exon 20 Group, a multistakeholder organization avatar

Exon 20 Group, a multistakeholder organization

@Exon20Group

Global org: patients/carers, HCPs, pharma, labs, scientists, working to cure #NSCLC #HER2 & #EGFR #Exon20 insertions (in 25 cancers +) marcia@exon20group.org

◷ Joined July 2017▧ 13 Photos and videos
Exon 20 Group, a multistakeholder organization avatar
Exon 20 Group, a multistakeholder organization@Exon20Group·26 Apr 2023

Don’t let your #EGFR #Exon20 and #HER2 #Exon20 patients miss out on the wonderful, caring community of patients and care partners (+ family members) in the multi-stakeholder @Exon20Group We have peer-to-peer counseling through our Angel Buddies program, oncology nursing services, weekly virtual meetings, and direct patient navigation plus 20 closed Facebook groups and Inspire. Ami and mobo as well as the drugs in the clinical trials pipeline are vitally important & manageable. We are looking for additional investigators, so let us know! Clinicians, molecular profiling labs welcome. Join our Exon 20 International Research Consortium! All services are free, exon20group.org & marcia@exon20group.org

Exon 20 Group, a multistakeholder organization avatar
Exon 20 Group, a multistakeholder organization@Exon20Group·11h

A very surprising rejection by the FDA.

It’s been a weird week. Planes grounded, Outlook down, and now @FDA declines to approve @SMMT_TX ivonescimab for EGFR-mutant lung cancer after osimertinib resistance (HARMONi trial). Despite a meaningful PFS benefit, lack of demonstrated OS benefit was the deciding factor — a challenging standard, particularly when other cancer drugs have been approved with similar PFS/OS discrepancies in this space 🤷🏽‍♀️ reuters.com/legal/litigation…

LUNG CONNECT powered by COR2ED avatar
⟳ Exon 20 Group, a multistakeholder organization retweeted
LUNG CONNECT powered by COR2ED@lung_connect·Nov 13

What do HCPs need to know about the evolving landscape of TROP2-directed ADCs in NSCLC? Take the e-learning to find out + earn #CME credit for your #cpd! 🎓 Register/access the programme: checkpoint.cor2ed.com/course… Discussion topics: - The relevance of TROP2 in metastatic #NSCLC - Clinical overview of TROP2-directed ADCs in NSCLC: -->> With and without actionable genomic alterations - Proactive AE monitoring and management - Best practice management Programme developed with #lungcancer experts, Prof. Nicolas Girard (@nicogirardcurie), Dr Louise Lim, Dr Jacob Sands (@sands_jacob) & Nurse Practitioner Mrs Stephanie McDonald 🤝Endorsed by @WarOnCancer, @Exon20Group & @BiomarkerCo Supported by an Independent Educational Grant from AstraZeneca #MedEd #Oncology #LCSM #MedTwitter #OncTwitter 📹

1:15
LUNG CONNECT powered by COR2ED avatar
⟳ Exon 20 Group, a multistakeholder organization retweeted
LUNG CONNECT powered by COR2ED@lung_connect·Nov 13

Did you catch the new data from WCLC 2026? Thoracic oncologist Dr @JSabari joined us at the congress to share insights on emerging data from DESTINY-Lung04, SOHO-01 & Beamion LUNG-1 Will new evidence change clinical practice? Watch the video to find out! 📺 Endorsed by @WarOnCancer , @Exon20Group & @BiomarkerCo Supported by an Independent Educational Grant from Bayer. For HCPs only.

5:14
Exon 20 Group, a multistakeholder organization avatar
Exon 20 Group, a multistakeholder organization@Exon20Group·Nov 14

Paulo chairs our @Exon20Group - Latin America and is a born advocate! We love him! Thank you, Paulo!

One of the most powerful moments of #LALCA26 @IASLC 🇧🇷 Paulo, a Brazilian patient advocate with @Exon20Group and caregiver, shared the heartbreaking lengths patients and families go through to access targeted therapies unavailable in #LATAM. Having patient advocates at the table is progress. Their voices are critical to advancing equitable access to cancer treatments. #GlobalOnc #Access

Post attachment
Exon 20 Group, a multistakeholder organization avatar
Exon 20 Group, a multistakeholder organization@Exon20Group·Nov 12

This is one of the most important papers of the year by one of the top teams @MSKCancerCenter in #histological #transformation to #SCLC--answering a question that had been looming over the field: science.org/doi/10.1126/scit…

Exon 20 Group, a multistakeholder organization avatar
Exon 20 Group, a multistakeholder organization@Exon20Group·Nov 12

One of our favorites--Chul Kim, MD at Georgetown on PAPILLON:

PAPILLON overall survival is in: first-line amivantamab plus chemotherapy posted the longest median OS reported to date in EGFR exon 20 insertion NSCLC. Chul Kim, MD breaks down what it means for frontline practice. Watch the OncLive® Rapid Readout: hubs.li/Q04zPvQT0 @chulkimMD @Lombardicancer #lcsm #Amivantamab #PAPILLON

0:15
Exon 20 Group, a multistakeholder organization avatar
Exon 20 Group, a multistakeholder organization@Exon20Group·Nov 12

Beautifully stated, so true!

You cannot be a great oncologist without a deep understanding of immunology. Cancer is not just a disease of mutated cells. It is also a battle between tumors and the immune system. From checkpoint inhibitors to CAR-T cells, modern oncology is increasingly built on immunology. Yet immunology remains underemphasized in oncology training. It’s time to make advanced immunology a mandatory pillar of oncology education.

LUNG CONNECT powered by COR2ED avatar
⟳ Exon 20 Group, a multistakeholder organization retweeted
LUNG CONNECT powered by COR2ED@lung_connect·Nov 11

Did you catch the new data from #WCLC2026? Thoracic oncologist Dr @JSabari joined us at the congress to share insights on emerging data from DESTINY-Lung04, SOHO-01 & Beamion LUNG-1 🫁 Will new evidence change clinical practice? Watch the video to find out! 📺 View/download Dr Sabari’s accompanying slides: cor2ed.com/lung-connect/prog… Endorsed by @WarOnCancer, @Exon20Group & @BiomarkerCo Supported by an Independent Educational Grant from Bayer. For HCPs only. #MedEd #thoraciconcology #lcsm #oncology #OncTwitter #WCLC26

5:14
Oncology Brothers avatar
⟳ Exon 20 Group, a multistakeholder organization retweeted
Oncology Brothers@OncBrothers·Nov 5

Amivantamab (SC) now @FDA✅ for 2L R/M HNSCC (HPV-unrelated) post plat + IO based on #OrigAMI4: - Ph1b/2, SC Ami mono (n=102) - ORR 42% (CR 15%). Historic 2L ORR 20-25% - mPFS 6.8mos, mOS 12.5mos - DoR NR (56% ≥6mo)! Much needed option. #OncTwittwer @OncUpdates @OncoAlert

Post attachment
LARVOL avatar
⟳ Exon 20 Group, a multistakeholder organization retweeted
LARVOL@Larvol·Nov 6

🚨Breaking🚨 FDA Grants Accelerated Approval to RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer fda.gov/news-events/press-an… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #HeadAndNeckCancer #HNC #RybrevantFaspro | @OncBrothers | @COlazagasti | @drdeniztural | @PaulJiL | @JiaJennyLiu

Post attachment
Exon 20 Group, a multistakeholder organization avatar
Exon 20 Group, a multistakeholder organization@Exon20Group·Nov 6

Congrats to Dr. Barbara Burtness at @YaleCancer and OrigAMI-4 patients, families, and study teams. This is a tremendous advance for recurrent/metastatic #HNSCC patients post plat chemo and anti-PD-(L)1. Accelerated approval based on ORR and DOR is merited, and we are thrilled for #HNSCC patients who can now benefit. Yet another solid tumor feather added to ami's cap.

This tweet is unavailable